studies

breast cancer - HER2-positive, lapatinib based treatment vs. placebo, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsTEACH (EGF105485), 2013 0.99 [0.74; 1.32] 0.99[0.74; 1.32]TEACH (EGF105485), 201310%3,147NAnot evaluable RFS/DFSdetailed resultsTEACH (EGF105485), 2013 0.83 [0.69; 0.99] 0.83[0.69; 0.99]TEACH (EGF105485), 201310%3,147NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-06-02 15:33 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 1304,421,1312,1326,1368,1373,1309,1302,1308